FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | Regulators

SPOTLIGHT: FDA extends Doribax review

March 7, 2008 — 7:59am ET
Tools


The FDA is extending its review of Johnson & Johnson's Doribax for pneumonia by three months. Regulators say the company has provided new information about the drug that needs to be assessed. Release


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about FDA   Regulators  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.